Market Place
Sourcing Support
Mallinckrodt Presents Data on TERLIVAZ® for Hepatorenal Syndrome
18 Nov 2024 //
PR NEWSWIRE
Mallinckrodt to Present at Jefferies London Healthcare Conference
14 Nov 2024 //
PR NEWSWIRE
Mallinckrodt Reports Q3 2024 Results & Full-Year Guidance
05 Nov 2024 //
PR NEWSWIRE
Mallinckrodt to Present TERLIVAZ® Data at AASLD Annual Meeting
30 Oct 2024 //
PR NEWSWIRE
Mallinckrodt Presents Terlivaz® Data For Hepatorenal Syndrome
29 Oct 2024 //
PR NEWSWIRE
Mallinckrodt Presents TERLIVAZ® Data in Hepatorenal Syndrome
26 Oct 2024 //
PR NEWSWIRE
Mallinckrodt to Report Earnings Results for Third Quarter 2024
24 Oct 2024 //
PR NEWSWIRE
Mallinckrodt Expands INOmax EVOLVE DS System In US Hospitals
10 Oct 2024 //
PR NEWSWIRE
Mallinckrodt Publishes Studies And Earns Ease Of Use Certification For Gel
17 Sep 2024 //
PR NEWSWIRE
THERAKOS CELLEX Photopheresis System Receives EU MDR CE Certification
03 Sep 2024 //
PR NEWSWIRE
Mallinckrodt Launches Acthar® Gel Single-Dose SelfJect™ Injector
06 Aug 2024 //
PR NEWSWIRE
Mallinckrodt Reports Q2 2024 Results And Raises Full Year Guidance
06 Aug 2024 //
PR NEWSWIRE
Mallinckrodt Sells Therakos® To CVC For $925 Million
06 Aug 2024 //
PR NEWSWIRE
Mallinckrodt to Report Earnings Results for Second Quarter 2024
01 Aug 2024 //
PR NEWSWIRE
BMJ report digs into Mallinckrodt`s opioid selling tactics
10 Jun 2024 //
FIERCE PHARMA
Mallinckrodt: TERLIVAZ Data In HRS Patients At EASL 2024
05 Jun 2024 //
PR NEWSWIRE
Mallinckrodt presents data on Terlivaz for inj with hepatorenal syndrome at 2024
20 May 2024 //
PHARMABIZ
Mallinckrodt Presents TERLIVAZ HRS Data At DDW 2024
18 May 2024 //
PR NEWSWIRE
Mallinckrodt Q1 2024 Results, Reaffirms Full-Year Guidance
09 May 2024 //
PR NEWSWIRE
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
14 Apr 2024 //
PR NEWSWIRE
Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel
11 Mar 2024 //
PR NEWSWIRE
Mallinckrodt Announces Appointment of Paul O`Neill as Executive Vice President
04 Mar 2024 //
PR NEWSWIRE
Mallinckrodt Announces U.S. FDA Approval of sNDA for Acthar
01 Mar 2024 //
PR NEWSWIRE
Mallinckrodt Announces Board of Directors and Leadership Updates
02 Feb 2024 //
PR NEWSWIRE
Mallinckrodt Presents New Data on TERLIVAZ for Injection at SCCM
22 Jan 2024 //
PR NEWSWIRE
Mallinckrodt Earns Top Score in Human Rights Campaign Foundation`s 2023-2024
27 Dec 2023 //
PR NEWSWIRE
Mallinckrodt Announces Journal Publication of Economic Evidence for TERLIVAZ
21 Dec 2023 //
PR NEWSWIRE
Mallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System
07 Dec 2023 //
PR NEWSWIRE
Mallinckrodt Completes Financial Restructuring
14 Nov 2023 //
PR NEWSWIRE
Drugmaker Mallinckrodt emerges from bankruptcy
14 Nov 2023 //
REUTERS
Mallinckrodt to Present Breadth of Data on TERLIVAZ (terlipressin) for Injection
08 Nov 2023 //
PR NEWSWIRE
Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
Mallinckrodt to Present Data on TERLIVAZ for Injection in Adult Patients
01 Nov 2023 //
PR NEWSWIRE
Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel
26 Oct 2023 //
PR NEWSWIRE
Mallinckrodt to Present Data on TERLIVAZ for Injection in Patients with HRS
22 Oct 2023 //
PR NEWSWIRE
Mallinckrodt wins court go-ahead for 2nd bankruptcy
11 Oct 2023 //
FIERCE PHARMA
Mallinckrodt Announces Publication of Two Journal Manuscripts for Acthar
10 Oct 2023 //
PR NEWSWIRE
Mallinckrodt Receives U.S. Court Approval for Financial Restructuring Plan
10 Oct 2023 //
PR NEWSWIRE
Mallinckrodt Receives FDA Approval for Lisdexamfetamine Dimesylate to ADHD
31 Aug 2023 //
PR NEWSWIRE
Mallinckrodt Receives Court Approval for "First Day" Motions to Ongoing Oper
30 Aug 2023 //
PR NEWSWIRE
Mallinckrodt plc Takes Next Step to Implement Financial Restructuring Plan
28 Aug 2023 //
PR NEWSWIRE
After $1.7B opioid deal, Mallinckrodt readies 2nd bankruptcy bid
23 Aug 2023 //
FIERCE PHARMA
Mallinckrodt considers Chapter 11 as ‘advanced discussions’ continue
16 Aug 2023 //
ENDPTS
Mallinckrodt plc Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
PR NEWSWIRE
Troubled Mallinckrodt continues to weigh its financial options
09 Aug 2023 //
FIERCE PHARMA
Mallinckrodt in talks with hedge funds to avoid opioid settlements
26 Jul 2023 //
REUTERS
Mallinckrodt faces lawsuit for allegedly misleading investors
14 Jul 2023 //
FIERCE PHARMA
Mallinckrodt to Present Data on TERLIVAZ
15 Jun 2023 //
PR NEWSWIRE
Mallinckrodt looking to delay $200 million opioid payment
15 Jun 2023 //
REUTERS
Drugmaker Mallinckrodt may file for bankruptcy again
03 Jun 2023 //
REUTERS
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection
01 Jun 2023 //
PR NEWSWIRE
Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection
08 May 2023 //
PR NEWSWIRE
Mallinckrodt Recognized as Industry Innovator at (NORD) 2023
05 May 2023 //
PR NEWSWIRE
Mallinckrodt to Report Earnings Results for First Quarter 2023
24 Apr 2023 //
PR NEWSWIRE
Mallinckrodt to Present New Retrospective Data on Effect of Acthar Gel
21 Mar 2023 //
PR NEWSWIRE
Mallinckrodt Reports Fourth Quarter and Fiscal 2022 Financial Results
28 Feb 2023 //
PR NEWSWIRE
Mallinckrodt to Present at Cowen`s 43rd Annual Health Care Conference
16 Feb 2023 //
PR NEWSWIRE
Mallinckrodt to Report Earnings Results for Fourth Quarter 2022
08 Feb 2023 //
PR NEWSWIRE
Mallinckrodt Appoints Dr. Peter Richardson, MRCP, as Chief Scientific Officer
12 Jan 2023 //
PR NEWSWIRE
Lupin appoints Spiro Gavaris as president of US generics biz
09 Dec 2022 //
ECONOMIC TIMES
